- Molecular NameAmantadine
- Synonym1-aminoadamantane; Adamantamine; Adamantanamine; Adamantylamine; Amantadine Base; Amantadine HCL; Amantadine Hydrochloride; Amantidine; Aminoadamantane
- Weight151.253
- Drugbank_IDDB00915
- ACS_NO768-94-5
- Show 3D model
- LogP (experiment)2.44
- LogP (predicted, AB/LogP v2.0)2.47
- pka10.1
- LogD (pH=7, predicted)-0.48
- Solubility (experiment)Slightly soluble
- LogS (predicted, ACD/Labs)(ph=7)0.65
- LogSw (predicted, AB/LogsW2.0)1.18
- Sw (mg/ml) (predicted, ACD/Labs)0.9
- No.of HBond Donors2
- No.of HBond Acceptors1
- No.of Rotatable Bonds0
- TPSA26.02
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn antiparkinsonian drug
- Absorption_value90.0
- Absorption (description)Slowly but almost completely absorbed after oral administration.
- Caco_2N/A
- Bioavailability79.0
- Protein binding67.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmThe major metabolic pathway is N-acetylation but several unusual routes (N-methylation, formation of Schiff bases and N-formates) have also been observed. Amantadine crosses the placenta and the blood–brain barrier. It is also distributed into breast milk.
- Half life10~15 h in patients with normal renal function but significantly prolonged in the elderly and in patients with renal impairment.
- ExcretionIt is mainly excreted unchanged in the urine (about 56% of a dose being excreted unchanged in 24 h and about 86% in 4 days) although small amounts of metabolites have also been detected.
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityAn adolescent who ingested 1.3 g of amantadine developed complex ventricular arrhythmias and altered mental status. The arrhythmias were completely suppressed with intravenous lidocaine. [L. Pimentel and B. Hughes,Pediatr. Emerg. Care,1991, 7, 89–92.]
- LD50 (rat)N/A
- LD50 (mouse)N/A